logo
Share SHARE
FONT-SIZE Plus   Neg

Cesca Therapeutics Prices Public Offering At $1.50 Per Unit

Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, announced that it priced an underwritten public offering of 7.53 million Units, consisting of an aggregate of 7.53 million shares of the Company's common stock and warrants to purchase 2.26 million shares of the Company's common stock, at a price of $1.50 per Unit.

Each warrant entitles the holder to purchase 0.30 of a share of common stock. The warrants will be exercisable immediately upon issuance at an exercise price of $1.55 per share and will expire five years from the date of issuance.

The shares of common stock and warrants comprising the Units are immediately separable. All of the Units in the offering are being sold by Cesca.

The gross proceeds to Cesca from this offering are expected to be approximately $11.3 million, excluding any future proceeds from the potential exercise of the warrants and before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cesca.

The offering is expected to close on or about June 18, 2014, subject to the satisfaction of customary closing conditions.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects. Alcobra Ltd.'s Investigational New Drug Applications for drug candidate MDX in Attention Deficit Hyperactivity Disorder and Fragile X Syndrome have been put on full clinical hold, following adverse neurological findings in a pre-clinical study.
comments powered by Disqus
Follow RTT